Press coverage about iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) has trended positive on Thursday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. iShares Nasdaq Biotechnology Index Fund earned a news sentiment score of 0.31 on Accern’s scale. Accern also assigned media headlines about the financial services provider an impact score of 45.8410355061324 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media stories that may have effected Accern’s analysis:
- Dow and tech-heavy Nasdaq diverge, crude moves ahead of supply report (finance.yahoo.com)
- Biotech Slump Could be a Buying Opportunity – ETF Trends (etftrends.com)
- Mid-Day ETF Update: ETFs, Stocks Mixed as Nasdaq, S&P 500 Turn Higher on Stronger Tech Stocks; Dow Wavers (nasdaq.com)
- Biotech: Expensive, But Not THAT Expensive (barrons.com)
- Is Now The Right Time To Invest In Financials And iShares Trust – iShares Nasdaq Biotechnology ETF (IBB)? (finance.yahoo.com)
Shares of iShares Nasdaq Biotechnology Index Fund (NASDAQ IBB) traded up $1.47 on Thursday, reaching $104.05. 2,132,168 shares of the company were exchanged, compared to its average volume of 3,288,204. iShares Nasdaq Biotechnology Index Fund has a 12-month low of $87.24 and a 12-month high of $114.17.
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Receive News & Ratings for iShares Nasdaq Biotechnology Index Fund Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology Index Fund and related companies with MarketBeat.com's FREE daily email newsletter.